Peter Calabresi, MD
Neurology · Burlington, VTNPI 1174581250
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,579 of the $97,693 with a category attached, or 84.5%. 6 manufacturers reported payments, led by Biogen at 43.9% of the total. Among neurology clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1177.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$43K
- Eli Lilly$36K
- Roche Diagnostics International Ltd$8K
- Novartis$6K
- Idorsia Pharmaceuticals US Inc$5K
- Siemens Medical Solutions USA, Inc.$24
Across 31 payments — averaging $111,776 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.3M
- Roche Diagnostics Corporation$75K
- Biogen$49K
What the payments were for
- Consulting fees$82,57985%
- Speaking & faculty fees$7,7678%
- Travel & lodging$5,6266%
- Food & beverage$1,7212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 42 | $42,870 |
| Eli Lilly | 27 | $35,947 |
| Roche Diagnostics International Ltd | 5 | $7,951 |
| Novartis | 6 | $6,000 |
| Idorsia Pharmaceuticals US Inc | 2 | $4,900 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,693 in reported general payments places this provider in the 95th percentile of 41 neurology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlatopaGlatiramer Acetate | 16 | $39,113 |
| Dalfampridine ErDalfampridine | 28 | $1,953 |
| Baclofen | 47 | $1,724 |
| Duloxetine Hcl | 14 | $862 |
| Olanzapine | 12 | $381 |
| Tizanidine Hcl | 11 | $237 |
| Fluoxetine Hcl | 16 | $211 |
| Gabapentin | 32 | $147 |
| Zolpidem Tartrate | 11 | $137 |
| Diazepam | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other neurology in Burlington
- Michael HehirBurlington$145K
- Andrew SolomonBurlington$142K
- Robert ShapiroBurlington$90K
- Rup TandanBurlington$53K
- Chantal Roy-HewitsonBurlington$51K
- Noah KolbBurlington$22K
- James BoydBurlington$20K
- Waqar WaheedBurlington$13K
- Robert HamillBurlington$7K
- Lisa BakerBurlington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.